Department of Pathology, College of Korean Medicine, Dong-eui University, Busan, South Korea.
Nutr Cancer. 2023;75(10):1945-1957. doi: 10.1080/01635581.2023.2272345. Epub 2023 Nov 30.
The roots of (TK) have been used in traditional oriental medicine for the treatment of respiratory diseases. In this study, we investigated whether an ethanolic root extract of TK (ETK) can regulate the metastatic potency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant human lung cancer cells. The relative migration and invasion abilities of erlotinib-resistant PC9 (PC9/ER) and gefitinib-resistant PC9 (PC9/GR) cells were higher than those of parental PC9 cells. Mesenchymal markers were overexpressed, whereas epithelial markers were downregulated in resistant cells, suggesting that resistant cells acquired the EMT phenotype. ETK reduced migration and invasion of resistant cells. The expression levels of N-cadherin and Twist were downregulated, whereas Claudin-1 was upregulated by ETK, demonstrating that ETK suppresses EMT. As a molecular mechanism, Src was dephosphorylated by ETK. The anti-metastatic effect of ETK was reduced by transfecting PC9/ER cells with a constitutively active form of c-Src. Dasatinib downregulated N-cadherin, Twist, and vimentin, suggesting that Src regulates EMT in resistant cells. Notably, CuB played a key role in mediating the anti-metastatic activity of ETK. Collectively, our results demonstrate that ETK can attenuate the metastatic ability of EGFR-TKI-resistant lung cancer cells by inhibiting Src-mediated EMT.
(TK)的根在传统的东方医学中被用于治疗呼吸道疾病。在这项研究中,我们研究了 TK 的醇提根提取物(ETK)是否可以调节表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)耐药的人类肺癌细胞的转移能力。与亲本 PC9 细胞相比,厄洛替尼耐药 PC9(PC9/ER)和吉非替尼耐药 PC9(PC9/GR)细胞的相对迁移和侵袭能力更高。耐药细胞中间充质标志物过度表达,而上皮标志物下调,表明耐药细胞获得了 EMT 表型。ETK 降低了耐药细胞的迁移和侵袭能力。ETK 下调了 N-钙黏蛋白和 Twist 的表达水平,而上调了 Claudin-1 的表达水平,表明 ETK 抑制了 EMT。作为一种分子机制,ETK 使Src 去磷酸化。用组成型激活形式的 c-Src 转染 PC9/ER 细胞后,ETK 的抗转移作用降低。Dasatinib 下调了 N-钙黏蛋白、Twist 和波形蛋白,表明 Src 调节耐药细胞中的 EMT。值得注意的是,CuB 在介导 ETK 的抗转移活性中起关键作用。总之,我们的研究结果表明,ETK 可以通过抑制 Src 介导的 EMT 来减弱 EGFR-TKI 耐药肺癌细胞的转移能力。